Barry R. Davis | Academic Influence

Barry R. Davis's AcademicInfluence.com Rankings

Barry R. Davis

Mathematics

#5944

World Rank

#8311

Historical Rank

Statistics

#577

World Rank

#657

Historical Rank

mathematics Degrees

Download Badge

Mathematics

Barry R. Davis's Degrees

Masters Statistics Stanford University
Bachelors Mathematics University of California, Berkeley

Similar Degrees You Can Earn

Best Online Bachelor's in Math 2025

Why Is Barry R. Davis Influential?

(Suggest an Edit or Addition)

According to Wikipedia, Barry Robert Davis is an American statistician and public health doctor specializing in the design, conduct, and analysis of clinical trials. He is Professor Emeritus of Biostatistics and Data Science at the University of Texas School of Public Health, where he served as Director of its Coordinating Center for Clinical Trials. He served as President of the Society for Clinical Trials in 2000 and as Chair of the Biometrics Section of the American Statistical Association in 2003.

(See a Problem?)

Barry R. Davis's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. (1996) (6618)
Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE Investigators. (1992) (5870)
Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). (2002) (5253)
Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials (2010) (1770)
Major cardiovascular events in hypertensive patients randomized to doxazosin vs chlorthalidone: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). ALLHAT Collaborative Research Group. (2000) (1367)
Major outcomes in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin vs usual care: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT-LLT). (2002) (1272)
Original Papers. Success and Predictors of Blood Pressure Control in Diverse North American Settings: The Antihypertensive and Lipid‐Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) (2002) (1039)
Cardiovascular events and their reduction with pravastatin in diabetic and glucose-intolerant myocardial infarction survivors with average cholesterol levels: subgroup analyses in the cholesterol and recurrent events (CARE) trial. The Care Investigators. (1998) (1015)
Effect of diuretic-based antihypertensive treatment on cardiovascular disease risk in older diabetic patients with isolated systolic hypertension. Systolic Hypertension in the Elderly Program Cooperative Research Group. (1996) (984)
Prevention of Heart Failure by Antihypertensive Drug Treatment in Older Persons With Isolated Systolic Hypertension (1997) (683)
Relation Between Red Blood Cell Distribution Width and Cardiovascular Event Rate in People With Coronary Disease (2008) (612)
Rationale and Design for the Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) (1996) (573)
Reduction of stroke incidence after myocardial infarction with pravastatin: the Cholesterol and Recurrent Events (CARE) study. The Care Investigators. (1999) (432)
Isolated systolic hypertension : prognostic information provided by pulse pressure. (1999) (422)
Relationship between plasma LDL concentrations during treatment with pravastatin and recurrent coronary events in the Cholesterol and Recurrent Events trial. (1998) (381)
Effects of captopril on ischemic events after myocardial infarction. Results of the Survival and Ventricular Enlargement trial. SAVE Investigators. (1994) (348)
Hydroxycarbamide versus chronic transfusion for maintenance of transcranial doppler flow velocities in children with sickle cell anaemia—TCD With Transfusions Changing to Hydroxyurea (TWiTCH): a multicentre, open-label, phase 3, non-inferiority trial (2016) (344)
Renal outcomes in high-risk hypertensive patients treated with an angiotensin-converting enzyme inhibitor or a calcium channel blocker vs a diuretic: a report from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). (2005) (328)
Change in depression as a precursor of cardiovascular events. SHEP Cooperative Research Group (Systoloc Hypertension in the elderly). (1996) (326)
Effect of treating isolated systolic hypertension on the risk of developing various types and subtypes of stroke: the Systolic Hypertension in the Elderly Program (SHEP). (2000) (321)
Long-term effect of diuretic-based therapy on fatal outcomes in subjects with isolated systolic hypertension with and without diabetes. (2005) (307)
Reduction of Stroke Events With Pravastatin: The Prospective Pravastatin Pooling (PPP) Project (2001) (300)
The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT): clinical center recruitment experience. (2001) (293)
Fasting glucose levels and incident diabetes mellitus in older nondiabetic adults randomized to receive 3 different classes of antihypertensive treatment: a report from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). (2006) (271)
Outcomes in Hypertensive Black and Nonblack Patients Treated With Chlorthalidone, Amlodipine, and Lisinopril (2005) (270)
Results of Prevention of REStenosis with Tranilast and its Outcomes (PRESTO) Trial (2002) (264)
Influence of Long-term, Low-Dose, Diuretic-Based, Antihypertensive Therapy on Glucose, Lipid, Uric Acid, and Potassium Levels in Older Men and Women With Isolated Systolic Hypertension The Systolic Hypertension in the Elderly Program (1998) (255)
Effect of antihypertensives on sexual function and quality of life: the TAIM Study. (1991) (250)
Clinical outcomes in antihypertensive treatment of type 2 diabetes, impaired fasting glucose concentration, and normoglycemia: Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). (2005) (248)
Safety and Tolerability of Pravastatin in Long-Term Clinical Trials: Prospective Pravastatin Pooling (PPP) Project (2002) (244)
Outcomes in hypertensive black and nonblack patients treated with chlorthalidone, amlodipine, and lisinopril. (2005) (244)
Visit-to-Visit Variability of Blood Pressure and Coronary Heart Disease, Stroke, Heart Failure, and Mortality (2015) (220)
Cardiovascular Outcomes in High-Risk Hypertensive Patients Stratified by Baseline Glomerular Filtration Rate (2006) (217)
Outcomes in Patients With Diabetes Mellitus Undergoing Percutaneous Coronary Intervention in the Current Era: A Report From the Prevention of REStenosis with Tranilast and its Outcomes (PRESTO) Trial (2004) (216)
Heart Failure With Preserved and Reduced Left Ventricular Ejection Fraction in the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (2008) (204)
Prevention of heart failure by antihypertensive drug treatment in older persons with isolated systolic hypertension. SHEP Cooperative Research Group. (1997) (190)
Pharmacological blood pressure lowering for primary and secondary prevention of cardiovascular disease across different levels of blood pressure: an individual participant-level data meta-analysis (2021) (181)
Clinical Events in High-Risk Hypertensive Patients Randomly Assigned to Calcium Channel Blocker Versus Angiotensin-Converting Enzyme Inhibitor in the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (2006) (165)
Serum lipids and incidence of coronary heart disease. Findings from the Systolic Hypertension in the Elderly Program (SHEP). (1996) (162)
Prevalence of Postural Hypotension at Baseline in the Systolic Hypertension in the Elderly Program (SHEP) Cohort (1991) (153)
Treatment-Resistant Hypertension and the Incidence of Cardiovascular Disease and End-Stage Renal Disease: Results From the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) (2014) (150)
Relation of low body mass to death and stroke in the systolic hypertension in the elderly program. The SHEP Cooperative Research Group. (2000) (140)
Atrial fibrillation at baseline and during follow-up in ALLHAT (Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial). (2009) (137)
I, RATIONALE AND DESIGN (1991) (136)
Rationale and design for the Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). ALLHAT Research Group. (1996) (136)
Pharmacogenetic Association of the Angiotensin-Converting Enzyme Insertion/Deletion Polymorphism on Blood Pressure and Cardiovascular Risk in Relation to Antihypertensive Treatment: The Genetics of Hypertension-Associated Treatment (GenHAT) Study (2005) (132)
The association of postural changes in systolic blood pressure and mortality in persons with hypertension: the Hypertension Detection and Follow-up Program experience. (1987) (128)
Role of Diuretics in the Prevention of Heart Failure: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (2006) (125)
The effect of statin therapy on heart failure events: a collaborative meta-analysis of unpublished data from major randomized trials (2015) (123)
Reduction in long-term antihypertensive medication requirements. Effects of weight reduction by dietary intervention in overweight persons with mild hypertension. (1993) (116)
Effect of Drug and Diet Treatment of Mild Hypertension on Diastolic Blood Pressure (1991) (114)
Uniformity of captopril benefit in the SAVE Study: subgroup analysis. Survival and Ventricular Enlargement Study. (1994) (110)
Clinical outcomes by race in hypertensive patients with and without the metabolic syndrome: Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). (2008) (108)
Glucose Variability in a 26-Week Randomized Comparison of Mealtime Treatment With Rapid-Acting Insulin Versus GLP-1 Agonist in Participants With Type 2 Diabetes at High Cardiovascular Risk (2016) (107)
Relationship of Antihypertensive Treatment Regimens and Change in Blood Pressure to Risk for Heart Failure in Hypertensive Patients Randomly Assigned to Doxazosin or Chlorthalidone: Further Analyses from the Antihypertensive and Lipid-Lowering treatment to prevent Heart Attack Trial (2002) (106)
Effect of Statin Treatment vs Usual Care on Primary Cardiovascular Prevention Among Older Adults: The ALLHAT-LLT Randomized Clinical Trial (2017) (103)
The Trial of Antihypertensive Interventions and Management (TAIM) Study. Final results with regard to blood pressure, cardiovascular risk, and quality of life. (1992) (101)
Pravastatin prevents clinical events in revascularized patients with average cholesterol concentrations. Cholesterol and Recurrent Events CARE Investigators. (1999) (101)
Protocol for prospective collaborative overviews of major randomized trials of blood-pressure-lowering treatments. World Health Organization-International Society of Hypertension Blood Pressure Lowering Treatment Trialists' Collaboration. (1998) (99)
Relation of metformin treatment to clinical events in diabetic patients undergoing percutaneous intervention. (2004) (96)
Persistence of reduction in blood pressure and mortality of participants in the Hypertension Detection and Follow-up Program. Hypertension Detection and Follow-up Program Cooperative Group. (1988) (94)
The Trial of Antihypertensive Interventions and Management (TAIM) study. Adequate weight loss, alone and combined with drug therapy in the treatment of mild hypertension. (1992) (92)
Effects of pravastatin on mortality in patients with and without coronary heart disease across a broad range of cholesterol levels. The Prospective Pravastatin Pooling project. (2002) (89)
Risk factors for stroke and type of stroke in persons with isolated systolic hypertension (1998) (86)
Cardiovascular Events and Their Reduction With Pravastatin in Diabetic and Glucose-Intolerant Myocardial Infarction Survivors With Average Cholesterol Levels Subgroup Analyses in the Cholesterol And Recurrent Events (CARE) Trial Clinical Investigation and Reports (1998) (85)
ALLHAT findings revisited in the context of subsequent analyses, other trials, and meta-analyses. (2009) (82)
Blood Pressure Control by Drug Group in the Antihypertensive and Lipid‐Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) (2008) (82)
Progression of kidney disease in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin versus usual care: a report from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). (2008) (81)
The prevalence of reduced glomerular filtration rate in older hypertensive patients and its association with cardiovascular disease: a report from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. (2004) (79)
Pharmacologic and nutritional treatment of mild hypertension: changes in cardiovascular risk status. (1990) (78)
Equalization of four cardiovascular risk algorithms after systematic recalibration: individual-participant meta-analysis of 86 prospective studies (2018) (78)
Cardiovascular and Renal Outcomes of Renin–Angiotensin System Blockade in Adult Patients with Diabetes Mellitus: A Systematic Review with Network Meta-Analyses (2016) (77)
Impact of mild or moderate chronic kidney disease on the frequency of restenosis: results from the PRESTO trial. (2004) (76)
The systolic hypertension in the elderly program (1994) (75)
Coronary heart disease risk factors in men and women aged 60 years and older: findings from the Systolic Hypertension in the Elderly Program. (1996) (75)
Influence of long-term, low-dose, diuretic-based, antihypertensive therapy on glucose, lipid, uric acid, and potassium levels in older men and women with isolated systolic hypertension: The Systolic Hypertension in the Elderly Program. SHEP Cooperative Research Group. (1998) (72)
Clinical Significance of Incident Hypokalemia and Hyperkalemia in Treated Hypertensive Patients in the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (2012) (72)
Research Needs to Improve Hypertension Treatment and Control in African Americans (2016) (72)
Long-term renal and cardiovascular outcomes in Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) participants by baseline estimated GFR. (2012) (72)
Validation of Heart Failure Events in the Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) Participants Assigned to Doxazosin and Chlorthalidone (2002) (71)
Sam68 RNA Binding Protein Is an In Vivo Substrate for Protein Arginine N-Methyltransferase 1 (2003) (71)
Long-Term Effects of Incident Diabetes Mellitus on Cardiovascular Outcomes in People Treated for Hypertension: The ALLHAT Diabetes Extension Study (2012) (70)
Association between chlorthalidone treatment of systolic hypertension and long-term survival. (2011) (68)
Cardiovascular Outcomes Using Doxazosin vs. Chlorthalidone for the Treatment of Hypertension in Older Adults With and Without Glucose Disorders: A Report From the ALLHAT Study (2004) (67)
Statins for Primary Prevention of Cardiovascular Disease in Elderly Patients: Systematic Review and Meta-Analysis (2015) (66)
Interrupted Time Series Analysis of Vancomycin Compared to Cefuroxime for Surgical Prophylaxis in Patients Undergoing Cardiac Surgery (2007) (66)
The Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) Heart Failure Validation Study: diagnosis and prognosis. (2007) (64)
Effect of antihypertensive therapy on weight loss. The Trial of Antihypertensive Interventions and Management Research Group. (1992) (62)
Age-stratified and blood-pressure-stratified effects of blood-pressure-lowering pharmacotherapy for the prevention of cardiovascular disease and death: an individual participant-level data meta-analysis (2021) (60)
Effects of hydroxyurea treatment for patients with hemoglobin SC disease (2016) (60)
Abstract 2734: Heart Failure with Preserved and Impaired Left Ventricular Systolic Function in the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) (2006) (60)
Blood pressure-lowering treatment strategies based on cardiovascular risk versus blood pressure: A meta-analysis of individual participant data (2018) (59)
Trial of antihypertensive intervention and management: greater efficacy with weight reduction than with a sodium-potassium intervention. (1993) (59)
Incidence and Predictors of Angioedema in Elderly Hypertensive Patients at High Risk for Cardiovascular Disease: A Report From the Antihypertensive and Lipid‐Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) (2006) (58)
The Association Between Antihypertensive Medication Nonadherence and Visit-to-Visit Variability of Blood Pressure: Findings From the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. (2016) (56)
A Phase II study of autologous mesenchymal stromal cells and c‐kit positive cardiac cells, alone or in combination, in patients with ischaemic heart failure: the CCTRN CONCERT‐HF trial (2021) (53)
Effect of Chlorthalidone, Amlodipine, and Lisinopril on Visit‐to‐Visit Variability of Blood Pressure: Results From the Antihypertensive and Lipid‐Lowering Treatment to Prevent Heart Attack Trial (2014) (53)
Cost efficacy of the diagnosis and therapy of renovascular hypertension. (1996) (53)
Trial of antihypertensive interventions and management. Design, methods, and selected baseline results. (1989) (53)
Long-Term Follow-Up of Participants With Heart Failure in the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) (2011) (52)
ALLHAT: Setting the Record Straight (2004) (52)
Thiazide-Type Diuretics and &bgr;-Adrenergic Blockers as First-Line Drug Treatments for Hypertension (2008) (52)
Impact of the ALLHAT/JNC7 Dissemination Project on thiazide-type diuretic use. (2010) (52)
Diabetes mellitus, smoking, and the risk for asymptomatic peripheral arterial disease: whom should we screen? (2005) (51)
Association of 3 Different Antihypertensive Medications With Hip and Pelvic Fracture Risk in Older Adults: Secondary Analysis of a Randomized Clinical Trial (2017) (50)
Major clinical trials of hypertension: what should be done next? (2005) (50)
Electrocardiographic Left Ventricular Hypertrophy Predicts Cardiovascular Morbidity and Mortality in Hypertensive Patients: The ALLHAT Study (2015) (49)
Upper bounds for type I and type II error rates in conditional power calculations (1990) (47)
Organ iron accumulation in chronically transfused children with sickle cell anaemia: baseline results from the TWiTCH trial (2016) (47)
Prediction of individual life-years gained without cardiovascular events from lipid, blood pressure, glucose, and aspirin treatment based on data of more than 500 000 patients with Type 2 diabetes mellitus. (2019) (47)
Renin predicts diastolic blood pressure response to nonpharmacologic and pharmacologic therapy. (1992) (45)
Dietary carotenoids and genetic instability modify bladder cancer risk. (2004) (44)
Pharmacogenetic Association of NOS3 Variants with Cardiovascular Disease in Patients with Hypertension: The GenHAT Study (2012) (44)
Mortality and Morbidity During and After the Antihypertensive and Lipid‐Lowering Treatment to Prevent Heart Attack Trial (2012) (43)
Visit-to-Visit Variability of BP and CKD Outcomes: Results from the ALLHAT. (2016) (43)
Participant recruitment in the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). (1998) (42)
High-Risk Cardiovascular Conditions in Sports-Related Sudden Death: Prevalence in 5,169 Schoolchildren Screened via Cardiac Magnetic Resonance. (2018) (41)
Disparities in Socioeconomic Context and Association With Blood Pressure Control and Cardiovascular Outcomes in ALLHAT (2019) (41)
Effect of atenolol and reserpine on selected events in the systolic hypertension in the elderly program (SHEP). (1995) (41)
Effect of statin treatment vs usual care on primary cardiovascular prevention among older adults ALLHAT-LLT randomized clinical trial (2017) (41)
Cost-effectiveness of Chlorthalidone, Amlodipine, and Lisinopril as First-step Treatment for Patients with Hypertension: An Analysis of the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) (2008) (40)
Analysis of a clinical trial involving a combined mortality and adherence dependent interval censored endpoint. (1992) (40)
TCD With Transfusions Changing to Hydroxyurea (TWiTCH): a multicentre, randomised controlled trial (2015) (39)
Blood pressure control and cardiovascular outcomes in normal-weight, overweight, and obese hypertensive patients treated with three different antihypertensives in ALLHAT (2014) (38)
Use of Repeated Blood Pressure and Cholesterol Measurements to Improve Cardiovascular Disease Risk Prediction: An Individual-Participant-Data Meta-Analysis (2017) (37)
Treatment-Resistant Hypertension and the Incidence of Cardiovascular Disease and End-Stage Renal DiseaseNovelty and Significance (2014) (37)
Coffee consumption and serum cholesterol in the hypertension detection and follow-up program. (1988) (37)
Systolic Hypertension in the Elderly Program (SHEP). Part 1: Rationale and design. (1991) (36)
Pharmacogenetic association of the NPPA T2238C genetic variant with cardiovascular disease outcomes in patients with hypertension. (2008) (35)
Interactions between the single nucleotide polymorphisms in the homocysteine pathway (MTHFR 677C>T, MTHFR 1298 A>C, and CBSins) and the efficacy of HMG-CoA reductase inhibitors in preventing cardiovascular disease in high-risk patients of hypertension: the GenHAT study (2008) (34)
Baseline characteristics of the diabetic participants in the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). (2001) (34)
The Systolic Hypertension in the Elderly Program (SHEP): an intervention trial on isolated systolic hypertension. SHEP Cooperative Research Group. (1989) (33)
Benazepril plus amlodipine or hydrochlorothiazide for hypertension. (2009) (33)
Long‐Term Follow‐Up of Moderately Hypercholesterolemic Hypertensive Patients Following Randomization to Pravastatin vs Usual Care: The Antihypertensive and Lipid‐Lowering Treatment to Prevent Heart Attack Trial (ALLHAT‐LLT) (2013) (32)
Pharmacogenetic Associations of MMP9 and MMP12 Variants with Cardiovascular Disease in Patients with Hypertension (2011) (32)
Visit‐to‐Visit Blood Pressure Variability and Cardiovascular Death in the Systolic Hypertension in the Elderly Program (2014) (32)
Blood pressure lowering and risk of new-onset type 2 diabetes: an individual participant data meta-analysis (2021) (32)
Lack of effectiveness of a low-sodium/high-potassium diet in reducing antihypertensive medication requirements in overweight persons with mild hypertension. TAIM Research Group. Trial of Antihypertensive Interventions and Management. (1994) (31)
Design of FLAT-SUGAR: Randomized Trial of Prandial Insulin Versus Prandial GLP-1 Receptor Agonist Together With Basal Insulin and Metformin for High-Risk Type 2 Diabetes (2015) (31)
Pharmacogenetic association of hypertension candidate genes with fasting glucose in the GenHAT Study (2010) (31)
Mortality and Morbidity During and After Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial: Results by Sex (2013) (30)
The Hypertension Detection and Follow-up Program design, methods, and baseline characteristics and blood pressure response of the study population. (1986) (29)
Magnetic Resonance Imaging-Based Screening Study in a General Population of Adolescents. (2018) (27)
The Impact of Antihypertensive Medications on Bone Mineral Density and Fracture Risk (2017) (27)
Investigating the stratified efficacy and safety of pharmacological blood pressure-lowering: an overall protocol for individual patient-level data meta-analyses of over 300 000 randomised participants in the new phase of the Blood Pressure Lowering Treatment Trialists’ Collaboration (BPLTTC) (2019) (26)
Long-Term Fatal Outcomes in Subjects With Stroke or Transient Ischemic Attack: Fourteen-Year Follow-Up of the Systolic Hypertension in the Elderly Program (2008) (26)
Characteristics and Long-Term Follow-Up of Participants with Peripheral Arterial Disease During ALLHAT (2014) (26)
Antecedent hypertension and the effect of captopril on the risk of adverse cardiovascular outcomes after acute myocardial infarction with left ventricular systolic dysfunction: Insights from the Survival and Ventricular Enlargement Trial. (2004) (26)
Pharmacogenetic Effect of the Stromelysin (MMP3) Polymorphism on Stroke Risk in Relation to Antihypertensive Treatment: The Genetics of Hypertension Associated Treatment Study (2011) (26)
Effects of Intensive Blood Pressure Treatment on Orthostatic Hypotension (2020) (26)
Antihypertensive treatment and risk of cancer: an individual participant data meta-analysis (2021) (25)
Antihypertensive treatment and risk of cancer: an individual participant data meta-analysis (2021) (25)
The Association Between Antihypertensive Medication Nonadherence and Visit-to-Visit Variability of Blood PressureNovelty and Significance (2016) (24)
Treatment resistant hypertension and the incidence of cardiovascular disease and end-stage renal disease: results from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) (2014) (23)
Liver iron concentration measurements by MRI in chronically transfused children with sickle cell anemia: baseline results from the TWiTCH trial (2015) (23)
Data monitoring in clinical trials: the case for stochastic curtailment. (1994) (23)
Differences in precision of dietary estimates among different population subgroups. (1993) (23)
Association of orthostatic hypertension with mortality in the Systolic Hypertension in the Elderly Program (2016) (22)
Getting clinical trial results into practice: design, implementation, and process evaluation of the ALLHAT Dissemination Project (2009) (22)
Absence of an interaction between the angiotensin-converting enzyme insertion-deletion polymorphism and pravastatin on cardiovascular disease in high-risk hypertensive patients: the Genetics of Hypertension-Associated Treatment (GenHAT) study. (2007) (21)
Prevalence and Correlates of Symptomatic Peripheral Atherosclerosis in Individuals with Coronary Heart Disease and Cholesterol Levels Less Than 240 mg/dL: Baseline Results from the Cholesterol And Recurrent Events (CARE) Study (1996) (21)
Conclusions and implications of the systolic hypertension in the elderly program. (1993) (21)
The effect of nine common polymorphisms in coagulation factor genes (F2, F5, F7, F12 and F13) on the effectiveness of statins: the GenHAT study (2009) (20)
Genetic Modifiers of White Blood Cell Count, Albuminuria and Glomerular Filtration Rate in Children with Sickle Cell Anemia (2016) (20)
Effects of Antihypertensive Class on Falls, Syncope, and Orthostatic Hypotension in Older Adults. (2019) (20)
Allogeneic Mesenchymal Cell Therapy in Anthracycline-Induced Cardiomyopathy Heart Failure Patients (2020) (19)
Drug-Gene Interactions of Antihypertensive Medications and Risk of Incident Cardiovascular Disease: A Pharmacogenomics Study from the CHARGE Consortium (2015) (19)
Antihypertensive pharmacogenetic effect of fibrinogen-beta variant −455G>A on cardiovascular disease, end-stage renal disease, and mortality: the GenHAT study (2009) (19)
Operational aspects of terminating the doxazosin arm of The Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). (2001) (19)
Survival analysis of adverse effects data in the Beta‐Blocker Heart Attack Trial (1987) (19)
Impaired Fasting Glucose and Body Mass Index as Determinants of Mortality in ALLHAT: Is the Obesity Paradox Real? (2014) (18)
Absence of a deleterious effect of calcium channel blockers in patients with left ventricular dysfunction after myocardial infarction: The SAVE Study Experience. SAVE Investigators. Survival and Ventricular Enlargement. (1998) (18)
TCD with Transfusions Changing to Hydroxyurea (TWiTCH): Hydroxyurea Therapy As an Alternative to Transfusions for Primary Stroke Prevention in Children with Sickle Cell Anemia (2015) (18)
ALLHAT: still providing correct answers after 7 years (2010) (18)
Gene panels to help identify subgroups at high and low risk of coronary heart disease among those randomized to antihypertensive treatment: the GenHAT study (2012) (18)
Genetic and Adverse Health Outcome Associations with Treatment Resistant Hypertension in GenHAT (2013) (17)
RYR3 gene polymorphisms and cardiovascular disease outcomes in the context of antihypertensive treatment (2012) (17)
Heterogeneity in Early Responses in ALLHAT (Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial) (2017) (16)
Effect of weight loss on thiazide produced erectile problems in men. (1990) (16)
Stroke outcomes among participants randomized to chlorthalidone, amlodipine or lisinopril in ALLHAT. (2014) (16)
Fractional Brownian motion and clinical trials (2000) (16)
Brownian motion and long-term clinical trial recruitment (2001) (16)
Cardiovascular risk assessment: addition of CKD and race to the Framingham equation. (2012) (16)
Risk factors for stroke and type of stroke in persons with isolated systolic hypertension. Systolic Hypertension in the Elderly Program Cooperative Research Group. (1998) (16)
Risk stratification of sudden cardiac death in hypertension. (2017) (15)
The Glycemic Effects of Antihypertensive Medications (2013) (15)
Abstract MP72: The Effects of Antihypertensive Class on Falls, Syncope, and Orthostatic Hypotension in Older Adults: the ALLHAT Trial (2019) (15)
Estimating Transition Probabilities for Ignorable Intermittent Missing Data in a Discrete-Time Markov Chain (2010) (15)
The effects of genes implicated in cardiovascular disease on blood-pressure response to treatment among treatment-naïve hypertensive African Americans in the GenHAT study (2015) (15)
Heart Failure in ALLHAT: Did Blood Pressure Medication at Study Entry Influence Outcome? (2009) (15)
Sex‐Specific Effects of AGT‐6 and ACE I/D on Pulse Pressure After 6 Months on Antihypertensive Treatment: The GenHAT Study (2007) (14)
Are 24 hours of ambulatory ECG monitoring necessary for a patient after infarction? (1988) (14)
Sustained blood pressure control and coronary heart disease, stroke, heart failure, and mortality: An observational analysis of ALLHAT (2019) (14)
OR-2: Risk and impact of incident glucose disorders in hypertensive older adults treated with an ace inhibitor, a diuretic, or a calcium channel blocker: a report from the allhat trial (2004) (13)
Bayesian analysis of multi-type recurrent events and dependent termination with nonparametric covariate functions (2017) (13)
Treatment-Resistant Hypertension and Outcomes Based on Randomized Treatment Group in ALLHAT. (2017) (13)
Experimental approaches to determining the choice of first-step therapy for patients with hypertension. The ALLHAT Research Group Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. (1996) (13)
Antihypertensive medications and risk of diabetes mellitus (2007) (13)
Prevention of Heart Failure in Hypertension—Disentangling the Role of Evolving Left Ventricular Hypertrophy and Blood Pressure Lowering: The ALLHAT Study (2019) (12)
Clinical Trial Design for Alpha-1 Antitrypsin Deficiency: A Model for Rare Diseases. (2015) (11)
Clinical and demographic correlates of medication and visit adherence in a large randomized controlled trial (2016) (11)
Statistical considerations in monitoring the Systolic Hypertension in the Elderly Program (SHEP). (1992) (11)
Part 1: Rationale and Design (1991) (11)
Electrocardiographic measures of left ventricular hypertrophy in the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. (2016) (11)
Competing cardiovascular and noncardiovascular risks and longevity in the systolic hypertension in the elderly program. (2014) (10)
Standardized physician preparation of death certificates. (1985) (10)
Blood pressure-lowering treatment for the prevention of cardiovascular events in patients with atrial fibrillation: An individual participant data meta-analysis (2020) (10)
Antihypertensive drug effects on long-term blood pressure: an individual-level data meta-analysis of randomised clinical trials (2022) (10)
The effects of angiotensinogen gene polymorphisms on cardiovascular disease outcomes during antihypertensive treatment in the GenHAT study (2014) (10)
Pharmacologic Prevention of Incident Atrial Fibrillation: Long-Term Results From the ALLHAT (Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial) (2017) (10)
P-444: Validation of heart failure events in ALLHAT participants assigned to doxazosin (2001) (10)
Imputing gene–treatment interactions when the genotype distribution is unknown using case‐only and putative placebo analyses—a new method for the Genetics of Hypertension Associated Treatment (GenHAT) study (2004) (10)
Association between chronic kidney disease and cancer mortality: A report from the ALLHAT. (2017) (9)
Pharmacogenetic effects of ‘candidate gene complexes’ on stroke in the GenHAT study (2014) (9)
Worsening of kidney function is the major mechanism of heart failure in hypertension: the ALLHAT study (2020) (9)
Should Antihypertensive Treatment Recommendations Differ in Patients With and Without Coronary Heart Disease? (from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial [ALLHAT]). (2016) (9)
Effect of the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) on Conduction System Disease. (2016) (9)
Management of High Blood Pressure in Clinical Practice: Perceptible Qualitative Differences in Approaches Utilized by Clinicians (2008) (8)
Effect of Antihypertensive Therapy on Weight Loss (2005) (8)
Statistical Methods That Distinguish between Attributes of Assessment (1992) (8)
Effects of Chronic Transfusion Therapy on MRI and MRA in Children with Sickle Cell Anemia at Risk for Primary Stroke: Baseline Imaging from the Twitch Trial (2014) (7)
Effect of antihypertensive drug treatment on long-term blood pressure reduction: An individual patient-level data meta-analysis of 352,744 Participants from 51 large-scale randomised clinical trials (2021) (7)
Extrahepatic Iron Deposition In Chronically Transfused Children With Sickle Cell Anemia – Baseline Findings From The Twitch Trial (2013) (7)
Blood pressure-lowering treatment for prevention of major cardiovascular diseases in people with and without type 2 diabetes: an individual participant-level data meta-analysis (2022) (7)
Variation in Serial TCD Velocity Measurements in the TCD with Transfusions Changing to Hydroxyurea (TWiTCH) Trial (2016) (7)
The Effects of eGFR Change on CVD, Renal, and Mortality Outcomes in a Hypertensive Cohort Treated With 3 Different Antihypertensive Medications (2018) (7)
Effects of Chronic Transfusion Therapy on transcranial Doppler Ultrasonography Velocities in Children with Sickle Cell Anemia at Risk for Primary Stroke: Baseline Findings from the Twitch Trial (2014) (7)
The Prognostic Value of the Duration of the Ambulatory Electrocardiogram after Myocardial Infarction (1988) (7)
Repeated confidence intervals and prediction intervals using stochastic curtailment (1992) (7)
Systolic hypertension in the elderly program (SHEP). X, Analysis (1991) (7)
In reply [4] (2006) (7)
Kidney function of transfused children with sickle cell anemia: Baseline data from the TWiTCH study with comparison to non‐transfused cohorts (2017) (6)
Adaptive group‐sequential design with population enrichment in phase 3 randomized controlled trials with two binary co‐primary endpoints (2019) (6)
Risk of Hospitalized Gastrointestinal Bleeding in Persons Randomized to Diuretic, ACE‐Inhibitor, or Calcium‐Channel Blocker in ALLHAT (2013) (6)
Physical working capacity after acute myocardial infarction in patients with low ejection fraction and effect of captopril. (1995) (6)
Legacy effect of delayed blood pressure lowering drug treatment in middle-aged adults with mildly elevated blood pressure: systematic review and meta-analysis (2020) (6)
A suicide epidemic model. (1986) (6)
Re: Hawkins RG, Houston MC Is population-wide diuretic use directly associated with the incidence of end-stage renal disease in the United States? A hypothesis. Am J Hypertens. 2005 Jun;18(6):744-9. (2006) (6)
The effects of antihypertensive class on gout in older adults: secondary analysis of the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. (2020) (5)
Rapid Decreases in Blood Pressure from Antihypertensive Treatment were Associated with Increased Cancer Mortality in the Systolic Hypertension in the Elderly Program (2014) (5)
Rapid eGFR change as a determinant of cardiovascular and renal disease outcomes and of mortality in hypertensive adults with and without type 2 diabetes. (2018) (5)
Autologous Cardiac Stem Cell Injection in Patients with Hypoplastic Left Heart Syndrome (CHILD Study) (2022) (5)
How much effect of different antihypertensive medications on cardiovascular outcomes is attributable to their effects on blood pressure? (2013) (5)
Does renin angiotensin system blockade deserve preferred status over other anti-hypertensive medications for the treatment of people with diabetes? (2016) (5)
Evaluating the effects of treatment switching with randomization as an instrumental variable in a randomized controlled trial (2017) (4)
Left Ventricular Noncompaction Detected by Cardiac Magnetic Resonance Screening: A Reexamination of Diagnostic Criteria. (2020) (4)
Analysis of Survival Data with Missing Measurements of a Time-Dependent Binary Covariate (2003) (4)
Systolic Hypertension of the Elderly Program (SHEP). Part 10: Analysis. (1991) (4)
Pravastatin and cardiovascular outcomes stratified by baseline eGFR in the lipid-lowering component of ALLHAT (2013) (4)
RESULTS OF MONOTHERAPY IN ALLHAT: ON-TREATMENT ANALYSES (2004) (4)
Yiddish and the Jewish Identity (1987) (4)
IS PSALM 110 A MESSIANIC PSALM ? (2005) (4)
OR 71: Results of monotherapy in allhat: On-treatment analyses (2004) (4)
Baseline Quality of Life and Risk of Stroke in the ALLHAT Study (Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial) (2017) (4)
Association of Sustained Blood Pressure Control with Multimorbidity Progression Among Older Adults (2020) (4)
Systolic hypertension in the elderly program (SHEP). I, Rationale and design (1991) (4)
Systolic Hypertension in the Elderly Program (SHEP). Part 7: Baseline laboratory characteristics. (1991) (3)
ALLHAT and calcium channel blockers. ALLHAT Research Group. (1997) (3)
Influence of Prevalent and Incident Atrial Fibrillation on Post-Trial Major Events in ALLHAT. (2017) (3)
Stochastically Curtailed Tests Under Fractional Brownian Motion (2015) (3)
Bayesian regression model for recurrent event data with event-varying covariate effects and event effect (2018) (3)
Response to Letter Regarding Article, “Role of Diuretics in the Prevention of Heart Failure: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT)” (2006) (3)
OR 70: Blood pressure control by randomized drug group in allhat (2004) (3)
The Blood Pressure Lowering Treatment Trialists’ Collaboration: methodological clarifications of recent reports (2022) (3)
Angiotensin-converting-enzyme inhibitors and diuretics for hypertension. (2003) (3)
Part 10: Analysis (1991) (3)
Real‐World Evidence Supports Optimally Dosed Thiazide‐Type Diuretics As Preferred in Treatment Regimens of Older Adults with Hypertension (2015) (3)
Omission of drug dose information. Authors' reply (2006) (2)
Yiddish: The Perils and Joys of Translation (2010) (2)
Angioedema in the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT) (2005) (2)
Should -blockers and diuretics remain as first line therapy for hypertension? (2008) (2)
Risk Factors Influencing Outcomes of Atrial Fibrillation in ALLHAT. (2017) (2)
Stopping rules versus conditional power (1988) (2)
Data Monitoring in the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial: Early Termination of the Doxazosin Treatment Arm (2006) (2)
Estimation of Protein Intake: Comparison of Dietary Assessment and Urinary Excretion (1990) (2)
Has oseltamivir been shown to be effective for treatment of H5N1 influenza? (2010) (2)
Prevention of Stroke in Older Persons With Isolated Systolic Hypertension-Reply (1991) (2)
Association of Sustained Blood Pressure Control with Lower Risk for High-Cost Multimorbidities Among Medicare Beneficiaries in ALLHAT (2021) (2)
The Glycemic Consequences of Antihypertensive Medications (2015) (1)
Abstract 14080: A Phase II Randomized, Double-blind, Controlled Trial of Combined Mesenchymal Stromal Cells and C-kit+ Cardiac Progenitor Cells in Ischemic Heart Failure: The CCTRN CONCERT-HF Trial (2020) (1)
Systolic hypertension in the elderly program (SHEP). VII, Baseline laboratory characteristics (1991) (1)
What If Chlorthalidone-Associated Hyperglycemia Develops?—Reply (2007) (1)
Iron inhibits replication of infectious hepatitis C virus in permissive Huh7.5.1 cells (2010) (1)
Stratified effects of blood pressure-lowering treatment on long-term blood pressure: an individual patient-level meta-analysis involving 50 randomised trials and 334,219 participants (2020) (1)
Variability of Inotropic and Chronotropic Response During Dobutamine Stress Echocardiography and Possible Implications for Diagnostic Accuracy (2003) (1)
THE CALIBRATION OF THE NORMAL MARGINAL DISUTILITY MODAL SPLIT MODEL (1974) (1)
FACTORS AFFECTING CHOICE OF TRAVEL MODE (1974) (1)
DAVID FRAM, YIDDISH POET 1903–1988 (2013) (1)
Conditional moving linear regression: Modeling the recruitment process for ALLHAT (2017) (1)
Research Output of the Canadian Pharmaceutical Industry: Where Has All the R&D Gone? Résultats de recherche dans l'industrie pharmaceutique canadienne : que sont devenus la recherche et le développement? (2006) (1)
Quality of life and antihypertensive therapy (1992) (1)
DID TYPE OF PRIOR ANTIHYPERTENSIVE THERAPY INFLUENCE THE HEART FAILURE RESULTS IN ALLHAT: 6A.6 (2004) (1)
Visit-to-visit variability of blood pressure and coronary heart disease, stroke, heart failure and mortality: results from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) (2014) (1)
25A The antihypertensive and lipid lowering treatment to prevent heart attack trial: Design features (1995) (1)
Secondary analyses in cardiovascular clinical trials - statistical and other considerations. Introduction. (2012) (1)
Sustained SBP control and long-term nursing home admission among Medicare beneficiaries (2021) (1)
Results of trials reporting a J-shaped relation between achieved blood pressure and incidence of coronary heart disease. (1990) (1)
Risk of Developing Alzheimer’s Disease and Related Dementias in ALLHAT Trial Participants Receiving Diuretic, ACE-Inhibitor, or Calcium-Channel Blocker with 18 Years of Follow-Up (2022) (1)
Part 7: Baseline Laboratory Characteristics (1991) (1)
Gender differences and similarities in effects of nonpharmacologic approaches to the treatment of mild hypertension (1995) (1)
Statistical reanalysis of vascular event outcomes in primary and secondary vascular prevention trials (2021) (1)
Abstract MP36: Effects Of Intensive Blood Pressure Treatment On Orthostatic Hypotension: An Individual-level Meta-analysis (2020) (1)
Decision rules for predicting future lipid values in screening for a cholesterol reduction clinical trial. (1996) (1)
Clinical trials in hypertension and related morbidities prediction of survival benefit of clinical trials (2015) (0)
Liver Iron Concentration By MRI In Chronically Transfused Children With Sickle Cell Anemia In The Twitch Trial (2013) (0)
Hypoglycemia prevention and user acceptance of an insulin pump system with predictive low glucose management (2017) (0)
The Systolic Hypertension in the Elderly Program (SHEP): Rationale, Design, Recruitment, and Baseline Data (1989) (0)
Nonparametric prediction analysis for binary data (1984) (0)
Genetic Modifiers Influencing the Development of Albuminuria in Children with Sickle Cell Anemia (2015) (0)
Response to Letter by Bath et al (2008) (0)
The Interaction of a Diabetes Gene Risk Score With 3 Different Antihypertensive Medications for Incident Glucose-level Elevation (2019) (0)
VISIT-TO-VISIT VARIABILITY OF SYSTOLIC BLOOD PRESSURE PREDICTS OUTCOMES MAINLY IN THE ACTIVE TREATMENT GROUP RATHER THAN THE PLACEBO GROUP IN THE SYSTOLIC HYPERTENSION IN THE ELDERLY PROGRAM: PATHOPHYSIOLOGIC IMPLICATIONS (2013) (0)
Pravastatin reduces mortality: The Prospective Pravastatin Pooling Project (2000) (0)
Visit to visit variability of the orthostatic response of systolic blood pressure is associated with increased risk of morbid and mortal events (2014) (0)
VII, BASELINE LABORATORY CHARACTERISTICS (1991) (0)
Advantages Of Bayesian Adaptive Trials For Comparative Effectiveness Research (CER): “RE-ADAPT”ING ALLHAT (2013) (0)
Pituitary cell transplantation (1996) (0)
Survival analysis of adverse effects data in the BHAT (1985) (0)
Trial the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Calcium Channel Blocker Versus Angiotensin-Converting Enzyme Inhibitor in Clinical Events in High-Risk Hypertensive Patients Randomly (2006) (0)
Hypertension artérielleHeart failure with preserved and reduced left ventricular ejection fraction in the antihypertensive and lipid-lowering treatment to prevent heart attack trial, B.R. Davis, J.B. Kostis, L.M. Simpson, et al., in: Circulation, 118 (2008), pp. 2259-2267 (2009) (0)
BLOOD PRESSURE-LOWERING, ANTIHYPERTENSIVE TREATMENT AND INCIDENT DIABETES (2021) (0)
Effects of captopril on mortality and morbidity rates in patients with left ventricular dysfunction following myocardial infarction: Results of survival and ventricular hypertrophic studies (1993) (0)
Trial Levels : Subgroup Analyses in the Cholesterol And Recurrent Events ( CARE ) Glucose-Intolerant Myocardial Infarction Survivors With Average Cholesterol Cardiovascular Events and Their Reduction With Pravastatin in Diabetic and (1998) (0)
Antihypertensive therapy's effect on the quality of life (1992) (0)
Influence of calcium channel blocker therapy on cardiovascular outcomes in the Cholesterol and Recurrent Events (CARE) trial (1998) (0)
P-400: Baseline characteristics of ALLHAT participants with impaired renal function: association with coexistent cardiovascular disease (2002) (0)
Abstract 11552: Statin Therapy in Patients With Type 2 Diabetes: Development and Validation of a Model to Predict Individualized Treatment Effects Based on the ASCOT, ALLHAT and CARDS Trials (2014) (0)
THE EFFECT OF RENAL FUNCTION ON INCIDENCE OF CONGESTIVE HEART FAILURE: THE ANTIHYPERTENSIVE AND LIPID-LOWERING TREATMENT TO PREVENT HEART ATTACK TRIAL (ALLHAT) STUDY (2020) (0)
Restenosis is not increased in mild or moderate chronic kidney disease: Results from the PRESTO trial (2003) (0)
Plans for analysis of the shep trial (1990) (0)
WIRKUNG VON CAPTOPRIL AUF MORTALITAT UND MORBIDITAT BEI PATIENTEN MIT LINKSVENTRIKULARER DYSFUNKTION NACH MYOKARDINFARKT. ERGEBNISSE DER 'SURVIVAL-AND-VENTRICULAR-ENLARGEMENT'-STUDIE (1992) (0)
Electrocardiographic Measures of Left Ventricular Hypertrophy in the Antihypertensive and Lipid-Lowering to Prevent Heart Attack Trial (2016) (0)
A Dynamic Risk Model for Multitype Recurrent Events. (2022) (0)
Abstract 18179: Predictors of Incident Pacemaker Implantation in the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) (2016) (0)
Abstract 13664: The Systolic Hypertension in the Elderly Program: Competing Cardiovascular and Non-Cardiovascular Risk and Increased Longevity (2012) (0)
Abstract 100: Hip and Pelvic Fracture Risk in Adults Treated with Three Different Classes of Antihypertensive Medications: The ALLHAT Study (2016) (0)
Abstract 13606: A New Right Bundle Branch Block in Hypertensive Patients on Doxazosin Mediates Congestive Heart Failure: The ALLHAT Study (2019) (0)
Systematic Reviews andMeta-and Pooled Analyses (2017) (0)
Abstract Sixth Annual Meeting Society for Clinical Trials May 12–15, 1985 Hyatt Regency, New Orleans, LouisianaStandardized physician preparation of death certificates (1985) (0)
New findings from completed studies and future directions — systolic hypertension in the elderly trial (shep) (1995) (0)
Abstract P220: Effects Of Orthostatic Hypotension On Intensive Blood Pressure Treatment With Respect To All-cause Mortality: An Individual-level Meta-analysis (2022) (0)
Impaired fasting glucose and body mass index as determinants of diabetes and mortality in the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT): is the obesity paradox real? (2014) (0)
Repeated confidence intervals and prediction intervals using stochastic curtailment under fractional Brownian motion (2016) (0)
Reduction of Stroke Incidence After Myocardial Infarction With Pravastatin The Cholesterol and Recurrent Events (CARE) Study Clinical Investigation and Reports (1998) (0)
Lipid Levels, Adherence to Medication, Baseline Characteristics in the Cholesterol and Recurrent Events (CARE) Study (1998) (0)
Author Response to Lipid‐Lowering in African Americans in ALLHAT—Optimism Bias? (2013) (0)
Baseline Characteristics of the Patients in the Two Treatment Groups * Placebo (2005) (0)
Should antihypertensive treatment recommendation differ for patients with and without coronary heart disease? report from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) (2014) (0)
Q In high risk patients with hypertension, what is the effect of chlorthalidone, amlodipine, and lisinopril on hospitalised or fatal heart failure (HF)? Does the effect differ across time and prespecified subgroups? (2007) (0)
Treatments for Hypertension Thiazide-Type Diuretics and -Adrenergic Blockers as First-Line Drug (2010) (0)
Angiotensin-converting enzyme inhibitors and diuretics: Optimal combination therapy [8] (multiple letters) (2004) (0)
A simulation study of the effects of small center enrollment in multi-center clinical trials (1998) (0)
2010 ASH Faculty (2010) (0)
62A Decision rules for predicting future lipid values in a cholesterol reduction clinical trial (1994) (0)
Abstract 14276: 30-Year Survival in the Active and Placebo Groups of the Systolic Hypertension in the Elderly Program (2016) (0)
H33 Relationship of body mass index to death and stroke among elderly hypertensives in the systolic hypertension in the elderly program (SHEP) (1997) (0)
Hepcidin generated by hepatoma cells inhibits iron export from co-cultured THP1 monocytes * (2006) (0)
Comment on: Is population-wide diuretic use directly associated with the incidence of end-stage renal disease in the united states? A hypothesis. by Hawkins RG et al (2006) (0)
STRATIFIED EFFECTS OF BLOOD PRESSURE-LOWERING TREATMENT ON LONG-TERM BLOOD PRESSURE: A META-ANALYSIS OF INDIVIDUAL-LEVEL DATA OF 334,219 PARTICIPANTS FROM 50 RANDOMIZED TRIALS (2021) (0)
Treatment to Prevent Heart Attack Trial : Results by Sex Mortality and Morbidity During and After Antihypertensive and Lipid-Lowering (2013) (0)
Should (cid:1) -blockers and diuretics remain as first line therapy for hypertension? Thiazide-Type Diuretics and (cid:1) -Adrenergic Blockers as First-Line Drug Treatments for Hypertension C ONTROVERSIES IN C ARDIOVASCULAR M EDICINE (2008) (0)
What if chlorthalidone-associated hyperglycemia develops? Authors' reply (2007) (0)
A Phase I Study of Allogeneic Mesenchymal Stem Cell Therapy in Patients with Heart Failure Secondary to Anthracycline-induced Cardiomyopathy: The Cctrn Stem Cell Injection in Cancer Survivors (Seneca) Trial (2020) (0)
Continuation of the trial of antihypertensive interventions and management: Design features (1990) (0)
Abstract 11020: Legacy Effects of Baseline Blood Pressure ‘Treatment Naivety’ on All-cause and Cardiovascular Mortality in the Antihypertensive and Lipid-lowering Treatment to Prevent Heart Attack Trial (ALLHAT) (2019) (0)
BRK phosphorylates PSF promoting its cytoplasmic localization and cell cycle arrest (2009) (0)
856: Dietary Carotenoids and Genetic Instability Modify Bladder Cancer Risk (2005) (0)
Effects of Posttrial Antihypertensive Drugs on Morbidity and Mortality: Findings from 15-Year Passive Follow-Up after ALLHAT Ended (2021) (0)
THE U-SHAPED RELATIONSHIP OF BODY MASS INDEX WITH ALL-CAUSE MORTALITY AT EIGHT YEARS IN THE ALLHAT (2017) (0)
Abstract W P172: Baseline Quality of Life and Risk of Stroke in the Antihypertensive and Lipid Lowering to Prevent Heart Attack (ALLHAT) Trial (2015) (0)
476 CARDIOVASCULAR OUTCOMES USING LISINOPRIL OR AMLODIPINE VERSUS CHLORTHALIDONE IN NORMAL WEIGHT, OVERWEIGHT, AND OBESE HYPERTENSIVE PATIENTS IN THE ALLHAT STUDY (2012) (0)
Abstract 16491: Predictors of Incident Conduction System Disease in the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) (2014) (0)
EFFECTS OF BLOOD PRESSURE-LOWERING ON CANCER RISK: AN INDIVIDUAL PARTICIPANT DATA META-ANALYSIS OF 300,000 PARTICIPANTS (2021) (0)
Lack of a significant legacy effect of baseline blood pressure 'treatment naivety' on all-cause and cardiovascular mortality in the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. (2020) (0)
HEME OXYGENASE-l AND ALZHEIMER DISEASE (2002) (0)
ORIGINAL INVESTIGATIONS Pathogenesis and Treatment of Kidney Disease Progression of Kidney Disease in Moderately Hypercholesterolemic, Hypertensive Patients Randomized to Pravastatin Versus Usual Care: A Report From the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALL (2008) (0)
Relation to Antihypertensive Treatment : The Genetics of Insertion / Deletion Polymorphism on Blood Pressure and Cardiovascular Risk in Pharmacogenetic Association of the Angiotensin-Converting Enzyme (2005) (0)
H40 Characteristics of the diabetic cohort in the ALLHAT study (1997) (0)
Risk of hospitalized and non-hospitalized gastrointestinal bleeding in ALLHAT trial participants receiving diuretic, ACE-inhibitor, or calcium-channel blocker (2021) (0)
Effects of Genetic Polymorphisms on Leukocyte and Neutrophil Counts and Maximum Tolerated Dose of Hydroxyurea in Children with Sickle Cell Anemia (2015) (0)
Heart Failure With Preserved and Reduced Left Ventricular Ejection Fraction in the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial Heart Failure (2008) (0)
George Whitefield's Doctrine of Scripture in Light of 18th Centtiry Biblical Criticism (1997) (0)
A bit of the world to come (2013) (0)
Qohelet 12 : 1-8--Death: an impetuous for life (2005) (0)
Local experience with LATM schemes (1986) (0)
Influence versus control :the role of the architect in urban design and development (1983) (0)
The holiness of God in the Psalms (1990) (0)
God Behind the Seen: Expositions of the Books of Ruth and Esther (1996) (0)

This paper list is powered by the following services:

Other Resources About Barry R. Davis

en.wikipedia.org

What Schools Are Affiliated With Barry R. Davis?

Barry R. Davis is affiliated with the following schools: